Urology News and Research

Latest Urology News and Research

Astellas' Protopic receives Health Canada approval for prevention of eczema flares

Astellas Pharma Canada, Inc. has announced that it has received approval from Health Canada for a new indication for its topical eczema therapy, Protopic® (tacrolimus ointment 0.03% and 0.1%). The new indication means that tacrolimus ointment can be prescribed for maintenance therapy to prevent flares and prolong flare free intervals in patients with moderate to severe atopic dermatitis (commonly called eczema).

17 Feb 2011

Sonablate HIFU device is now available in Brazil to treat prostate cancer

USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 medical device, announces that HIFU with the Sonablate is available to prostate cancer patients for the first time in Brazil at Hospital Nossa Senhora das Gracas in Curitiba, capital city of the state of Parana in southern Brazil.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Endo Pharmaceuticals and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin.

16 Feb 2011

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

An analysis of data including more than 500,000 adults indicates that levels in the blood of bilirubin in the normal range but relatively higher were associated with a reduced risk of lung cancer, chronic obstructive pulmonary disease and all-cause death, according to a study in the February 16 issue of JAMA.

15 Feb 2011

FDA clears ArthroCare's Spartan 5.5 Needled Anchor

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration for its Spartan 5.5 Needled Anchor. Spartan is a preloaded threaded anchor indicated for use in fixation of soft tissue to bone, such as during a rotator cuff repair.

15 Feb 2011

Aesthetic and dental surgical procedures show greater than average growth

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, standouts in surgical procedures in terms of growth over the next five years are going to be dental implant, facial injectable, optical coherence tomography (OCT) catheter, spinal nonfusion implant, and percutaneous heart valve procedures in North America.

15 Feb 2011

Studies reveal markers for measuring ability of children with ADHD to control impulsive movements

Two research studies published today in Neurology®, the medical journal of the American Academy of Neurology, found markers for measuring the ability of children with Attention Deficit Hyperactivity Disorder (ADHD) to control impulsive movements, which may reveal insights into the neurobiology of ADHD, inform prognosis and guide treatments.

15 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

ArthroCare fourth quarter total revenue increases to $92.6 million

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the fourth quarter and year ended December 31, 2010.

14 Feb 2011

Seven-year study demonstrates clear benefits of fetal surgery to treat spina bifida in babies

Results of a landmark, seven-year National Institutes of Health-funded trial, Management of Myelomeningocele Study (MOMS), demonstrate clear benefit for babies who undergo fetal surgery to treat spina bifida, the most common birth defect in the central nervous system.

11 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

US District Court rules in favor of Watson in generic Mucinex patent infringement suit

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida has ruled that Watson's generic versions of Mucinex®, Mucinex® D and Mucinex® DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and Pseudoephedrine/Guaifenesin) Extended-Release products, do not infringe U.S. Patent No. 6,372,252.

10 Feb 2011

New study: Fetal surgery for spina bifida greatly improves child's mobility

Performing delicate surgery in the womb, months before birth, can substantially improve outcomes for children with a common, disabling birth defect of the spine. Experts at The Children's Hospital of Philadelphia co-led a new landmark study showing that fetal surgery for spina bifida greatly reduces the need to divert fluid from the brain, improves mobility and improves the chances that a child will be able to walk independently.

9 Feb 2011

Study finds dutasteride not cost-effective in prevention of prostate cancer in men at elevated risk

The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

9 Feb 2011

MRI Medical announces name change to Xeridiem Medical Devices

MRI Medical Inc. is changing its name to Xeridiem Medical Devices, Inc. as part of its corporate development plan.

9 Feb 2011

Study shows dogs can be trained to detect PCa by smelling urine

In the February 2011 issue of European Urology, Jean-Nicolas Cornu and colleagues reported the evaluation of the efficacy of prostate cancer detection by trained dogs on human urine samples.

8 Feb 2011

Patients with kidney tumours can benefit from nephron-sparing surgery

Patients with kidney tumours larger than four centimetres are much more likely to enjoy good long-term renal function if they undergo nephron-sparing surgery rather than radical nephrectomy, according to a study in the February issue of the urology journal BJUI.

7 Feb 2011

Microsulis' Microwave Endometrial Ablation platform sold to Hologic

Microsulis Medical Limited announced this week that it has exclusively licensed to Hologic Inc all rights to its microwave technology in the gynecology and female urology fields of use.

From Hologic, Inc. 5 Feb 2011

American Cancer Society report released on World Cancer Day

A new American Cancer Society report says cancers associated with lifestyles and behaviors related to economic development, including lung, breast, and colorectal cancers, will continue to rise in developing countries if preventive measures are not widely applied. The finding comes from the second edition of Global Cancer Facts & Figures and its academic publication, Global Cancer Statistics, published in CA: A Cancer Journal for Clinicians.

4 Feb 2011